Identity
- Security key
- 14834
- Ticker
- EOLS
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2018-02-08
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- EOLS
Detail
Enriched 2026-08-14 20:47
- Market cap
- $536,329,572.8
- Shares outstanding (class)
- 66,050,440
- Shares outstanding (weighted)
- 66,050,440
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 353
- Location
- NEWPORT BEACH, CA
- Homepage
- https://www.evolus.com
- Description
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.